Merck didn’t design calderasib to be the most potent KRAS G12C inhibitor on its own. It was designed to be the most combinable inhibitor. The KRAS gene encodes a protein that signals for cell growth. It cycles between active and inactive states, signaling when cells should divide. Although it is one of the most commonly…
Beyond PD-1: The drugs reshaping cancer treatment at ASCO 2026
Biotech is heating up again. The SPDR S&P Biotech ETF (XBI) has gained roughly 69% over the past year. Global life sciences M&A hit $240 billion in 2025, an 81% jump from the prior year, with EY reporting a record $2.1 trillion in deal capacity. Goldman Sachs expects broader M&A volume to rise sharply in…

